Life Tech Sees Clinical Promise for NGS Panels, Exomes; Says Multiple Platforms to Drive Dx Strategy | GenomeWeb

Life Technologies is fleshing out a strategy to build out its medical sciences business across multiple technology platforms, including next-gen sequencing, qPCR, CE sequencing, and fluorescent in situ hybridization, leveraging its installed base of around 7,500 genetic analysis instruments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.